New Triple-Threat Cancer Therapy Kills 70% of Breast Cancer Cells in Lab Tests

A new cancer treatment has shown promising results in lab tests by combining chemotherapy with two types of heat therapy. Researchers found that this approach could kill up to 70% of breast cancer cells within three days. The findings were published in the journal Advanced NanoBiomed Research. The study focused on a trimodal therapy that attacks cancer in three ways at once. Scientists used doxorubicin, a common chemotherapy drug, while applying two forms of heat: magnetic hyperthermia and near-infrared radiation. Both methods raise the temperature of cancer cells, which are more sensitive to heat than healthy ones.

By combining these treatments, the team achieved high cell death rates with lower doses of doxorubicin. This reduces the drug's harmful side effects on the rest of the body. The experiments were carried out on breast cancer cells outside a living organism, meaning further testing would be needed before human trials. Despite the encouraging results, no current clinical trials or research groups are known to be working on similar multimodal hyperthermia therapies for cancer. The approach remains experimental for now, with no immediate plans for wider testing or development.

The trimodal method offers a potential way to fight cancer more effectively while cutting down on toxic side effects. The study's success in lab conditions suggests it could be explored further in future research. However, no active projects on this specific treatment have been identified so far.